Comparative Pharmacology
Head-to-head clinical analysis: DISOBROM versus DISOPHROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOBROM versus DISOPHROL.
DISOBROM vs DISOPHROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DISOBROM is a synthetic compound that acts as a partial agonist at benzodiazepine sites on GABAA receptors, potentiating GABAergic neurotransmission. It also exhibits antagonistic activity at peripheral benzodiazepine receptors (TSPO).
Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.
DISOBROM is not a recognized drug. Please verify the name.
1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 3-4 hours in adults; in renal impairment, half-life may be prolonged up to 8-12 hours requiring dose adjustment.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (20-30%); fecal excretion accounts for <10%.
Renal excretion of unchanged drug and metabolites; approximately 60-70% of a dose eliminated in urine as unchanged drug and glucuronide conjugates, with <10% in feces.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine/Decongestant Combination